Dear Shareholder,
On 27 May 2022, the board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) invited you to (virtually) attend the annual general meeting on 30 June 2022 (the “AGM”), at offices of the Company at Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands.
The Board notices that the drafts of the Annual Report and the Annual Accounts for the financial year 2021 will unfortunately not be available in time for the upcoming AGM and therefore these documents as such cannot be approved and adopted, as the case may be, by the general meeting.
Hoofddorp, the Netherlands, 15 June 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
Hoofddorp, the Netherlands, 8th June 2022. Today IGEA Pharma N.V. (SIX: IGPH) has signed a preliminary agreement with LMH Spa for a Euro 6.000.000 commitment to fund the completion of its GMP-Pharma CBD extraction facility owned through its joint-venture Blue Sky Swisse S.A.
Dear Shareholder,
The board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) hereby invites you to (virtually) attend the annual general meeting on 30 June 2022 (the “AGM”), at offices of the Company at Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands. The meeting will start at 10:00 hours CEST. Registration will start at 9:30 hours CEST.
Hoofddorp, the Netherlands, 2 May 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
Hoofddorp, the Netherlands, 1February 2022. Today the Board of Directors of IGEA Pharma N.V. (SIX: IGPH) has acknowledged the resignation of Mrs Giovanna Puppo, Mr Raffaele Bertoni, Mr Lieven Baten and Mr Massimiliano Colella as members of the Board of Directors. The resignation is effective as of 31 January 2022 and is motivated by personal reasons.
Hoofddorp, the Netherlands, 25 November 2021. IGEA Pharma N.V. (SIX: IGPH) receives an analyst vote. On Monday 22nd the research house GBC AG (www.gbc-ag.de/) publishes its first coverage equity research on the Company and from now on, GBC analysts Matthias Greiffenbergerand Felix Haugg will cover the further development of Igea Pharma NV with continuous assessment.
Hoofddorp, the Netherlands, 04October 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that GBCAG (www.gbc-ag.de/) will begin a full-coverage equity research on the Company.